SGLT2抑制剂恩格列净未能改善MRLlpr/lpr小鼠活动性狼疮肾炎
本研究在自发系统性红斑狼疮活动性狼疮肾炎的雌性MRLlpr/lpr小鼠中,于第9至13周出现活动性LN征象后随机给予恩格列净10 mg/kg/天或不予治疗,共4周。结果显示恩格列净增加尿糖和饮水量,但未改变血糖、体重、摄食、肾小球滤过率、白蛋白尿、肾小球IgG沉积、LN活动或慢性指数及间质纤维化。提示SGLT2抑制剂可能不影响LN活动性,而应针对LN的慢性肾脏病方面。
要点
- 恩格列净未改善活动性LN小鼠的蛋白尿或肾功能。
- 恩格列净未改变LN活动指数、慢性指数或间质纤维化。
- SGLT2抑制剂或应定位为针对LN的CKD方面。
核心结论
- 在活动性LN的MRLlpr/lpr小鼠中,恩格列净不影响蛋白尿、肾脏排泄功能或狼疮征象。
- SGLT2抑制剂可能不影响LN活动性,而应被视为针对LN的慢性肾脏病方面以预防进一步肾单位丢失。
研究设计与样本
- 雌性MRLlpr/lpr小鼠为自发系统性红斑狼疮伴活动性LN模型。
- 第9至13周出现活动性LN征象后随机分为恩格列净10 mg/kg/天组或未治疗对照组,治疗4周。
- 活动性LN征象定义为尿蛋白>100 mg/dl(试纸++)或至少两个双侧部位(颈部、肱部或腹股沟)淋巴结肿大伴尿蛋白>30 mg/dl。
主要发现
- 恩格列净增加MRLlpr/lpr小鼠尿糖和饮水量,但未影响血糖、体重或摄食。
- 治疗4周后,恩格列净未改变肾小球滤过率、白蛋白尿、肾小球IgG沉积、LN活动或慢性指数及间质纤维化。
临床怎么用
- SGLT2抑制剂在活动性LN中可能不降低LN活动性,临床应考虑其针对LN慢性肾脏病方面以预防肾单位丢失。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Sodium glucose cotransporter 2 inhibitors (SGT2i) have delayed the progression of chronic kidney disease with or without diabetes. However, its effect in active glomerulonephritis such as lupus nephritis (LN) is unknown. Here, we tested the effect of the SGLT2i empagliflozin (EMP) in MRLlpr/lpr mice, a model of spontaneous systemic lupus erythematosus with active LN. METHODS: Female MRLIpr/lpr mice were treated with 10 mg/kg/day of the EMP for four weeks. To better mimic the patient setting, MRLIpr/lpr mice were randomly assigned to EMP or untreated control group between weeks nine and 13 once the signs of active LN appeared. Proteinuria levels over 100 mg/dl (++ in reactive strips) or lymphadenopathy in minimum two bilateral sites (cervical, branchial or inguinal) with proteinuria over 30mg/dl were considered as signs of an active LN. Lymphadenopathy, body weight, water and food intake were monitored weekly. Blood glucose was measured bi-weekly, while glomerular filtration rate and albumin-to-creatinine ratio were obtained at the beginning and at the end of the experiment. RESULTS: EMP treatment increased glycosuria and water intake in MRLlpr/lpr mice, but did not affect blood glucose levels, body weight, or food intake. After four weeks of treatment, EMP did not alter glomerular filtration rate, albuminuria, histological glomerular IgG deposits, activity or chronicity indexes of LN, or interstitial fibrosis in MRLlpr/lpr mice. CONCLUSIONS: Our results indicate that EMP does not affect proteinuria or kidney excretory function nor signs of lupus in MRLlpr/lpr mice with active LN. This suggests that SGLT2i may not affect LN activity, and they should be, rather, considered to target the chronic kidney disease aspect of LN to prevent further nephron loss.
引用
- Vilardell-Vilà J, Jacobs-Cachá C, Martos-Guillamí N, et al. Sodium glucose cotransporter 2 inhibition does not improve active lupus nephritis in MRLlpr/lpr mice. Kidney Int. 2025. PMID: 41176090. doi:10.1016/j.kint.2025.09.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。